Adhesion Barrier Market Overview
The global adhesion barrier market size was valued at $541.3 million in 2017 and is expected to exhibit a CAGR of 7.5% during the forecast period. The market growth is mainly driven by the increasing volume of surgeries, rise in geriatric population, and advancements in technology.
The adhesion barrier market has been categorized into two product types: synthetic and natural. These products are used to prevent post-surgical adhesions. Synthetic products held a larger share in the market during the historical period, with a contribution of 67.2% revenue in 2017. This can be mainly attributed to the advantageous properties of synthetic products, such as higher flexibility and bioabsorbability.
GLOBAL ADHESION BARRIER MARKET, BY PRODUCT, $M (2013-2023)
Based on formulation, the adhesion barrier market has been categorized into film, gel, and liquid solutions. Of these, film formulations are expected to observe the fastest growth in demand during the forecast period, with 8.0% CAGR. This growth can be mainly attributed to the increasing demand for film-based formulations for surgical procedures due to their lower cost and higher level of efficacy and safety, as compared to gel and liquid adhesion prevention formulations.
Adhesion barriers find wide application in gynecological, general/abdominal, orthopedic, cardiovascular, neurological, urological, reconstructive, and other surgeries. Adhesion prevention products used for gynecological surgeries held the largest share, of 23.0%, in the global market in 2017. This can be ascribed to the increase in the use of anti-adhesive products in intrauterine and peritoneal surgeries, owing to the high risk for peritoneal adhesions associated with these surgeries.
Globally, North America is expected to continue holding the largest share in the adhesion barrier market. This can be mainly attributed to the increasing number of surgical procedures, rising number of road accidents, increasing prevalence of chronic diseases, and surging healthcare expenditure in the region.
Adhesion Barrier Market Dynamics
With increase in the prevalence of chronic diseases and other health conditions, the number of surgeries performed globally has also risen considerably in recent years. Film, gel, and liquid adhesion prevention formulations are used in a number of surgical procedures, such as gynecological and abdominal surgeries. These formulations are used on the surgical site to separate internal tissues and organs during the healing process and prevent post-surgical adhesions. Thus, they act as a physical barrier to separate traumatized tissue surfaces and enhance tissue healing. The demand for these products is increasing due to the rise in the volume of surgeries performed across the world.
According to a publication by the World Health Organization (WHO), around 266.2–359.5 million surgeries were performed globally in 2012. The number is expected to increase in the coming years, due to the increasing prevalence of chronic diseases, such as cardiovascular diseases and arthritis. Chronic diseases require surgical intervention as a therapeutic procedure. Hence, the rising number of surgical procedures is expected to continue driving the growth of the adhesion barrier market in the near future.
Besides, the growing prevalence of sports injuries is escalating the demand for these products. Sprains and strains are the most common types of sports injuries reported globally. According to Stanford Children’s Health, a San Francisco-based healthcare system focusing on pediatric and obstetric care, more than 3.5 million injuries in the U.S. occur in 30 million children participating in any organized sport and one-third of all injuries that occur during childhood are sports related. Thus, the increase in the number of surgical procedures for the treatment of sports injuries is spurring the demand for adhesion prevention products, which, in turn, is driving the growth of the adhesion barrier market.
The regulatory requirements for the affiliation of medical devices are complex and undergo amendments with changing needs. These regulations are complicated, primarily because of the legal aspects associated with them. The quality and performance of medical devices are necessary facets that need stringent evaluation to ensure public safety. Thus, complex and stringent standards are followed for the affiliation of medical devices.
According to the United States Food and Drug Administration (USFDA), resorbable adhesion barrier is a significant risk device, as defined in 21 Code for Regulations (CFR) 812.3(m)(4). The resorbable adhesion barrier is a class III device that is required to undergo several procedures for approval, as defined by the USFDA, including investigational device exemption (IDE), premarket approval (PMA), and product development protocol (PDP). Since the regulatory process, at times, consumes too much time for the approval of medical devices, the research and development (R&D) of these devices gets hampered. Thus, stringent regulatory requirements restrict the growth of the adhesion barrier market to some extent.
Adhesion Barrier Market Competitive Landscape
With a number of technological advancements taking place in the adhesion barrier industry, the players are seeking approvals and introducing new and advanced adhesion prevention products. For instance, in July 2018, FzioMed Inc. announced the enrolment of patients for a study to check the efficacy and safety of Oxiplex, an adhesion prevention product for use in the lumbar surgery. The trial is aimed at obtaining the U.S. approval for the company’s product.
In April 2018, Integra LifeSciences Holdings Corporation introduced its extended portfolio of the Codman specialty surgical products at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans, U.S. The products showcased by the company included adhesion prevention solutions, such as DuraSeal, DuraGen and DuraFlex.
Some of the other key players operating in the adhesion barrier industry are Medtronic plc, Sanofi, Johnson & Johnson, Getinge AB, Baxter International Inc., C.R. Bard Inc., MAST Biosurgery AG, and Anika Therapeutics Inc.